title: Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy.
authors: Heartcenter Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, The Netherlands.
authors: Freek W A
authors: FW
authors: Verheugt
authors: Peter
authors: P
authors: Clemmensen
authors: Roxana
authors: R
authors: Mehran
authors: Stefan
authors: S
authors: Agewall
authors: Stuart J
authors: SJ
authors: Pocock
authors: Sidney
authors: S
authors: Goldstein
authors: Christian
authors: C
authors: Torp-Pedersen
authors: Maarten L
authors: ML
authors: Simoons
authors: Jeffrey S
authors: JS
authors: Borer
authors: Yasser M
authors: YM
authors: Khder
authors: Paul
authors: P
authors: Burton
authors: Efthymios
authors: E
authors: Deliargyris
authors: John J V
authors: JJ
authors: McMurray
authors: Scott D
authors: SD
authors: Berkowitz
authors: Wendy Gattis
authors: WG
authors: Stough
authors: Faiez
authors: F
authors: Zannad
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D005544:Forecasting; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D061214:Patient Safety; D058921:Purinergic P2Y Receptor Antagonists / Q000009:adverse effects; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D058921:Purinergic P2Y Receptor Antagonists